

INTROGEN THERAPEUTICS INC

Form 8-K

May 11, 2004

Table of Contents

**SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 11, 2004

Introgen Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware

0-21291

74-2704230

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

301 Congress Avenue, Suite 1850, Austin, Texas

78701

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code: (512) 708-9310

(Former name or former address, if changed since last report)

TABLE OF CONTENTS

Item 7. Financial Statements and Exhibits.

Item 12. Results of Operations and Financial Condition.

SIGNATURES

INDEX TO EXHIBITS

Press Release

Table of Contents

Item 7. Financial Statements and Exhibits.

(c) Exhibits.

99.1 Press Release dated May 11, 2004.

Item 12. Results of Operations and Financial Condition.

On May 11, 2004, Introgen Therapeutics, Inc. issued a press release announcing financial results for the quarter ended March 31, 2004. A copy of this press release is attached hereto as Exhibit 99.1.

The information in this Current Report on Form 8-K is being furnished and shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 11, 2004

INTROGEN THERAPEUTICS, INC.

/s/ James W. Albrecht, Jr.
James W. Albrecht, Jr.
Chief Financial Officer

-2-

Table of Contents

INDEX TO EXHIBITS

Exhibit Number	Description of Document
99.1	Press Release dated May 11, 2004.